Clearside Biomedical names well-known pharm industry financial executive, Jeffrey Edwards, to its board

handshake-business-finance_615726896.jpg

Clearside Biomedical (NASDAQ:CLSD) named Jeffrey Edwards to its board, effective immediately.

Mr. Edwards, a veteran of the global pharmaceuticals industry, spent 21 years at Allergan in positions of increasing responsibility, including EVP, finance and business development, and CFO from 2005 to 2014. He continued as a non-executive officer of Allergan until his retirement in February 2015.

While at Allergan, he was the recipient of several awards, including Institutional Investor – Specialty Pharmaceutical Industry, Best CFO (2008, 2009); Institutional Investor –Pharmaceutical Industry, Best CFO (2010, 2013, 2015); Wall Street Journal – Top CFO’s in America (2012); and Brendan Wood International Investor Confidence - Healthcare Companies, Top CFO (2011, 2014).

Mr. Edwards has extensive corporate governance experience and currently serves on the boards of publicly traded companies - Bio-Rad Laboratories and FibroGen - as well as on the board of Viamet Pharmaceuticals Holdings, a closely-held biopharmaceutical company.

“As we prepare to submit our first NDA, increase our commercial readiness and advance our late-stage pipeline, Jeff’s strategic, operational and financial expertise will be a tremendous asset to our team and to our shareholders,” Clearside chairman, William Humphries, said in a statement.

Mr. Edwards succeeds Evgeny Zaytsev, M.D.

Mr. Humphries said Dr. Zaytsev, who joined the board in August 2014, championed an anchor investment in Clearside’s Series B financing by RMI Partners, a venture capital company with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies.

“In the time that I have worked with Evgeny, he has earned my deep personal admiration and great professional respect. I wish him continued success,” said Mr. Humphries.

Melane LaBelle Sampson